实用肝脏病杂志
實用肝髒病雜誌
실용간장병잡지
JOURNAL OF CLINICAL HEPATOLOGY
2014年
1期
55-57
,共3页
慢性丙型肝炎%聚乙二醇干扰素α-2a%利巴韦林%疗效
慢性丙型肝炎%聚乙二醇榦擾素α-2a%利巴韋林%療效
만성병형간염%취을이순간우소α-2a%리파위림%료효
Chronic hepatitis C%Pegylated interferon α-2b%Ribavirin%Therapeutic effect
目的：对比长效干扰素联合利巴韦林与普通干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效及安全性。方法回顾性分析60例慢性丙型肝炎患者的临床资料，其中长效干扰素组采用聚乙二醇干扰素α-2a （PEG-INFα-2a）联合利巴韦林进行抗病毒治疗（n=30例），普通干扰素组采用普通IFNα-2a联合利巴韦林治疗（n=30例），均分别于治疗4、12、24、48w及治疗结束后24w评价疗效，并观察药物的不良反应。结果长效干扰素组持续病毒学应答率（SVR）为90.0%，显著高于普通干扰素组的56.7%（P<0.01）；两组药物不良反应均有发热、肌肉酸痛、脱发及中性粒细胞、血小板下降等，但长效干扰素组发生发热和肌肉酸痛比率分别为36.7%和33.3%，显著低于普通干扰素组（90.0%和93.3%，P<0.01）；长效干扰素组中性粒细胞下降明显高于普通干扰素组，在4～24w尤其明显。结论长效干扰素联合利巴韦林治疗方案疗效显著优于普通干扰素联合利巴韦林，且未增加不良反应。
目的：對比長效榦擾素聯閤利巴韋林與普通榦擾素聯閤利巴韋林治療慢性丙型肝炎的臨床療效及安全性。方法迴顧性分析60例慢性丙型肝炎患者的臨床資料，其中長效榦擾素組採用聚乙二醇榦擾素α-2a （PEG-INFα-2a）聯閤利巴韋林進行抗病毒治療（n=30例），普通榦擾素組採用普通IFNα-2a聯閤利巴韋林治療（n=30例），均分彆于治療4、12、24、48w及治療結束後24w評價療效，併觀察藥物的不良反應。結果長效榦擾素組持續病毒學應答率（SVR）為90.0%，顯著高于普通榦擾素組的56.7%（P<0.01）；兩組藥物不良反應均有髮熱、肌肉痠痛、脫髮及中性粒細胞、血小闆下降等，但長效榦擾素組髮生髮熱和肌肉痠痛比率分彆為36.7%和33.3%，顯著低于普通榦擾素組（90.0%和93.3%，P<0.01）；長效榦擾素組中性粒細胞下降明顯高于普通榦擾素組，在4～24w尤其明顯。結論長效榦擾素聯閤利巴韋林治療方案療效顯著優于普通榦擾素聯閤利巴韋林，且未增加不良反應。
목적：대비장효간우소연합리파위림여보통간우소연합리파위림치료만성병형간염적림상료효급안전성。방법회고성분석60례만성병형간염환자적림상자료，기중장효간우소조채용취을이순간우소α-2a （PEG-INFα-2a）연합리파위림진행항병독치료（n=30례），보통간우소조채용보통IFNα-2a연합리파위림치료（n=30례），균분별우치료4、12、24、48w급치료결속후24w평개료효，병관찰약물적불량반응。결과장효간우소조지속병독학응답솔（SVR）위90.0%，현저고우보통간우소조적56.7%（P<0.01）；량조약물불량반응균유발열、기육산통、탈발급중성립세포、혈소판하강등，단장효간우소조발생발열화기육산통비솔분별위36.7%화33.3%，현저저우보통간우소조（90.0%화93.3%，P<0.01）；장효간우소조중성립세포하강명현고우보통간우소조，재4～24w우기명현。결론장효간우소연합리파위림치료방안료효현저우우보통간우소연합리파위림，차미증가불량반응。
Objective To compare the efficacy and safety of pegylated interferon-α2a (PEG-INF α-2a) or INF α-2a combined with ribavirin in treatment of patients with chronic hepatitis C (CHC). Methods 30 patients with CHC were treated with PEG-INF α-2a and 30 with INF α-2a,and all were combined with ribavirin;The ef-ficacy of each treatment was observed at 4,12 and 48 weeks. The rate of sustained virologic response (SVR) and the adverse reactions were evaluated 24 weeks after treatment termination. Results The SVR in PEG-INF α-2a group was 90.0%,significantly higher than that in INF α-2a group (56.7%,P<0.01);Adverse reaction such as fever,muscular soreness,hair loss and decline in neutrophils and platelet counts were observed in both groups, but the incidences of fever and muscular soreness in PEG-INF α-2a treated patients were 36.7% and 33.3%, respectively,which were significantly lower than that in INF α-2a treated patients (P<0.05);The rate of decline of neutrophils in PEG-INFα-2a treated patients,from 4 to 24 weeks,was more obvious than that in INF α-2a group. Conclusion PEG-INFα-2a plus ribavirin shows better efficacy for CHC without a significant increase in adverse reactions.
